TALA-125
/ Talawar Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 06, 2026
TALA‑125, a high‑affinity bispecific antibody co‑neutralising IL‑13 and IL‑18 with an extended half‑life: preclinical characterisation for atopic dermatitis
(EADV 2026)
- No abstract available
Bispecific • Preclinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IL13
1 to 1
Of
1
Go to page
1